

BOLETIM RAMB COVID-19

Número 41
26 de novembro de 2020

Comparative evaluation of memory T cells in COVID- 19 patients and the predictive role of CD4⁺CD8⁺ double positive T lymphocytes as a new marker

*Yasin Kalpakci
Tuba Hacibekiroglu
Gulay Trak
Cengiz Karacaer
Taner Demirci*

*Havva Kocayigit
Cenk Sunu
Ceyhun Varim
Mesude Falay*

Em um momento em que há uma emergência mundial de saúde pública, é fundamental que o conhecimento científico gerado durante a pandemia chegue rapidamente à classe médica classe médica.

Dentro desta dinâmica a Revista da Associação Médica Brasileira (Ramb) está adotando uma série de medidas a fim de acelerar o processo editorial para publicação de artigos sobre a Covid-19. A partir de hoje (14/04/2020), a AMB publicará o Boletim Ramb Covid-19, que antecipará os artigos científicos selecionados pelos editores da Ramb sobre o tema.

“Os artigos foram escritos por especialistas e selecionados dentro dos critérios da Ramb para esclarecer temas fisiopatológicos, assim como oferecer orientações de prevenção e tratamento da doença. Dessa forma, esperamos colaborar com os médicos para o melhor atendimento aos seus pacientes, com a disponibilidade mais ágil desses artigos, antes de sua publicação na Ramb”, comenta Carlos Serrano Jr., editor-chefe da Ramb.

Para o diretor científico da AMB, Antonio Carlos Palandri Chagas, “neste momento ímpar vivido no mundo por conta da pandemia de Covid-19, a AMB cumpre seu papel de estar levando à comunidade científica brasileira os recentes artigos sobre os mecanismos fisiopatológicos e aspectos clínicos relevantes dessa situação que assola a saúde pública”.



Carlos Serrano Jr.



Antonio Carlos Palandri Chagas

EDITORIAL BOARD

EDITORS-IN-CHIEF

Carlos V. Serrano Jr.
José Maria Soares Jr.

CO-EDITOR

Wanderley M. Bernardo

MANAGING EDITOR

César Teixeira

ASSOCIATED EDITORS

Albert Bousso
Sérgio C. Nahas
Auro Del Giglio

Claudia Leite

Edna Frasson de S. Montero

Eduardo F. Borba

Elias Jirjoss Ilias

Isabela Giuliano

Lucia Pellanda

Paulo Kassab

Werther B. W. de Carvalho

Linamara Batistella

Dimas Ikeoki

Anna Andrei

Maria Laura Costa do Nascimento

Benedito Borges da Silva

INTERNATIONAL EDITORS

Frida Leonetti

Geltrude Mingrone

Giuseppe Barbaro

Marcelo Marotti

Walter Ageno

Michael Farkouh

JUNIOR EDITORS

Matheus Belloni Torsani

Hélio Amante Miot

Rubens Zeron

Luiz de Menezes Montenegro

Gustavo K. Matsui

SPECIALTY EDITORS

ACUPUNCTURE

Ari Ojeda Ocampo Moré
Pedro Cavalcante
Dirceu de Lavôr Sales
Marcia Lika Yamamura
Hildebrando Sábato
Fernando Claudio Genschow

ALLERGY AND IMMUNOLOGY

Herberto José Chong Neto
Luis Felipe Chiaverini Ensina
Pedro Francisco Giavina-Bianchi Júnior

ANAESTHESIOLOGY

Marcos Antonio Costa de Albuquerque
Maria Angela Tardelli
Maria José Carvalho Carmona
Rogean Rodrigues Nunes

ANGIOLOGY AND VASCULAR SURGERY

Marcelo Fernando Matielo
José Fernando Macedo
José Aderval Aragão
Arno Von Ristow
Daniel Mendes Pinto

CARDIOLOGY

Wolney de Andrade Martins
Olimpio Ribeiro França Neto
Otavio Rizzi Coelho Filho
Pedro Silvio Farsky
Humberto Graner Moreira

CARDIOVASCULAR

Eduardo Augusto Victor Rocha
João Carlos Ferreira Leal
Rui M. S. Almeida

CLINICAL PATHOLOGY / LABORATORY MEDICINE

Álvaro Pulchinelli Júnior
Maria Elizabete Mendes
Marinês Dalla Valle Martino
Silvana Maria Elói Santos

COLOPROCTOLOGY

Fábio G. Campos
Sergio Nahas

DERMATOLOGY

Mauro Yoshiaki Enokihara
Flávia Bittencourt

DIGESTIVE ENDOSCOPY

Adriana Safatle

DIGESTIVE SURGERY

Bruno Zilberstein
Nelson Andreollo
Oswaldo Malafaia
Carlos Eduardo Jacob

EMERGENCY MEDICINE

Hélio Penna Guimarães
Marcus Vinicius de Andrade
Júlio Marchini

ENDOCRINOLOGY AND METABOLISM

Márcio Mancini
Manoel Ricardo Alves Martins

FAMILY AND COMMUNITY MEDICINE

Thiago Sarti
Leonardo Fontenelle

GASTROENTEROLOGY

João Galizzi Filho
André Castro Lyra
Raquel Canzi Almada de Souza

GENERAL SURGERY

Luiz Carlos Von Bahten
Pedro Eder Portari Filho
Rodrigo Felipe Ramos

GERIATRICS AND GERONTOLOGY

Vitor Last Pintarelli

GYNAECOLOGY AND OBSTETRICS

César Eduardo Fernandes
Corintio Mariani Neto
Rosiane Mattar
Edmund Chada Baracat

HAND SURGERY

João Baptista Gomes dos Santos
Samuel Ribak
Antonio Carlos da Costa

HEAD AND NECK SURGERY

Antonio Jose Gonçalves
Flávio Carneiro Hojaij
José Guilherme Vartanian
Leandro Luongo Matos

HEMATOLOGY AND HEMOTHERAPY

Fernando Ferreira Costa

HOMEOPATHY

Silvia Irene Waisse Priven

INFECTIOUS DISEASES

Helio Bacha
Alexandre Vargas Schwarzbald

INTENSIVE CARE MEDICINE

Rosane Sonia Goldwasser
Cintia Magalhães Carvalho Grión
Claudio Piras

INTERNAL MEDICINE

Fernando Sabia Tallo
Abrão José Cury Junior

LEGAL MEDICINE AND MEDICAL EXAMINATIONS

Ivan Dieb Miziara
José Jozafra B. Freite

MASTOLOGY

Gil Facina
Rene Aloisio da Costa Vieira
Ruffo de Freitas Junior

MEDICAL GENETICS

Vera Lucia Gil da Silva Lopes

NEUROSURGERY

Luis Alencar B. Borba
Jean Gonçalves de Oliveira
José Carlos Esteves Veiga

José Marcus Rotta

Eberval Gadelha Figueiredo
Benedicto Oscar Colli

NEPHROLOGY

Andrea Pio de Abreu
Vinicius Daher Alvares Delfino
David Jose de Barros Machado

NEUROLOGY

Carlos Roberto de Mello Rieder
Marcondes Cavalcante França Jr.

NUCLEAR MEDICINE

Juliano Julio Cerci
Cristina Sebastião Matushita
George Barberio C. Filho
Rafael Willain Lopes

NUTROLOGY

Elza Daniel de Mello
Juliana Machado
Durval Ribas Filho

OCCUPATIONAL MEDICINE

Francisco Cortes Fernandes
Rosylane Nascimento das Mercês Rocha
Andrea Franco Amoras Magalhães

ONCOLOGY

Daniela Rosa
Markus Gifoni
Romualdo Barroso

OPHTHALMOLOGY

Keila Monteiro de Carvalho
Eduardo Melani Rocha

ORTHOPAEDICS AND TRAUMATOLOGY

Marco Kawamura Demange
Benno Ejnisman
Daniel Soares Baumfeld
Alex Guedes
Robinson Esteves Santos Pires

OTOLARYNGOLOGY

Marcio Nakanishi
Luciano Rodrigues Neves
Vinicius Ribas de Carvalho Duarte
Fonseca
Edson Ibrahim Mitre

PAEDIATRIC

Emanuel Savio Cavalcanti Sarinho
Debora Carla Chong e Silvia
Simone Brasil de Oliveira Iglesias

PAEDIATRIC SURGERY

Maria do Socorro Mendonça de Campos
Lisieux Eyer de Jesus
José Roberto de Souza Baratella

PATHOLOGY

Fernando Augusto Soares
Kátia Ramos Moreira Leite

PHYSICAL MEDICINE AND REHABILITATION

Silvia Verst
Eduardo Rocha
Luciana Dotta

Ligia Cattai

Marcus Yu Bin Pai

PLASTIC SURGERY

Ricardo Frota Boggio
Rodrigo Gouvea Rosique
Fabio Kamamoto

PREVENTIVE MEDICINE AND HEALTH ADMINISTRATION

Antonio Eduardo Fernandes D'Aguilar
Milton Massayuki Osaki
Helio Komagata

PSYCHIATRY

Antônio Geraldo da Silva
Itiro Shirakawa
Francisco Baptista Assumpção Junior
Leonardo Rodrigo Baldaçara
Sérgio Tamai

PULMONOLOGY / PHTHISIOLOGY

José Miguel Chatkin
Marcelo Fouad Rabahi
Rodrigo Luis Barbosa Lima
Rosemeri Maurici da Silva

RADIOTHERAPY

Arthur Accioly Rosa
Gustavo Nader Marta
Gustavo Viani Arruda
Mauricio Fraga da Silva

RADIOLOGY

Alair Sarmet
Valdir Muglia
Dante Luiz Escussato
Luciana Costa Silva
Claudia Leite
Manoel Rocha

RHEUMATOLOGY

Eduardo dos Santos Paiva

SPORTS MEDICINE

André Pedrinelli;
Fernando Carmelo Torres
Marcelo Bichels Leitão.

SURGICAL ONCOLOGY

Alexandre Ferreira Oliveira
Reitan Ribeiro
Gustavo Andrezza Laporte

TRAFFIC MEDICINE

José Heverardo da Costa Montal
Arlison de Souza Carvalho Junior
Egas Caparelli Moniz de Aragão Dáquer

THORACIC SURGERY

Darcy Pinto
Carlos Alberto Araujo
Ricardo Terra

UROLOGY

Eduardo Carvalhal
Gilberto Almeida
Stênio Zequi
Lucas Teixeira A. Batista
Francisco Bretas

**ASSOCIAÇÃO MÉDICA BRASILEIRA (BRAZILIAN MEDICAL ASSOCIATION)
MANAGEMENT BOARD 2017-2020**



PRESIDENT

Lincoln Lopes Ferreira (Minas Gerais)

1ST VICE-PRESIDENT

Diogo Leite Sampaio (Mato Grosso)

2ND VICE-PRESIDENT

Robson Freitas de Moura (Bahia)

VICE-PRESIDENTS

José Luiz Dantas Mestrinho – Mid-West (Federal District)

Arno Buertiner Von Ristow – Southeast (Rio de Janeiro)

Eduardo Francisco de Assis Braga – North (Tocantins)

Mauro Cesar Viana de Oliveira – Northeast (Maranhão)

Alfredo Floro Cantalice Neto – South (Rio Grande do Sul)

GENERAL SECRETARY

Antônio Jorge Salomão (São Paulo)

1ST SECRETARY

Carmita Helena Najjar Abdo (São Paulo)

1ST TREASURER

Miguel Roberto Jorge (São Paulo)

2ND TREASURER

José Luiz Bonamigo Filho (São Paulo)

CULTURAL DIRECTOR

Fernando Antonio Gomes de Andrade (Alagoas)

DIRECTOR OF CORPORATE RELATIONS

Carlos Alfredo Lobo Jasmin (Rio de Janeiro)

DIRECTOR OF INTERNATIONAL RELATIONS

Eduardo Nagib Gaudi (Rio de Janeiro)

SCIENTIFIC DIRECTOR

Antonio Carlos Palandri Chagas (São Paulo)

ACADEMIC DIRECTOR

Maria José Martins Maldonado (Mato Grosso do Sul)

DIRECTOR OF MEMBER SUPPORT SERVICES

Marcio Silva Fortini (Minas Gerais)

DIRECTOR OF PARLIAMENTARY AFFAIRS

Débora Eugenia Braga Nóbrega Cavalcanti (Paraíba)

**RAMB - REVISTA DA ASSOCIAÇÃO MÉDICA BRASILEIRA
(JOURNAL OF THE BRAZILIAN MEDICAL ASSOCIATION)**

RAMB

EDITORS-IN-CHIEF: *Carlos V. Serrano Jr. and José Maria Soares Jr.*

CO-EDITOR: *Wanderley M. Bernardo*

MANAGING EDITOR: *César Teixeira*

E-MAIL: *ramb@amb.org.br*

WEBSITE: *www.ramb.org.br*

Address: Rua São Carlos do Pinhal, 324

Bela Vista – São Paulo

Postal Code: 01333-903

Phone no.: (+55 11) 3178-6800 Ext. 177

The RAMB, Journal of The Brazilian Medical Association, is an official publication of the Associação Médica Brasileira (AMB – Brazilian Medical Association), indexed in Medline, Science Citation Index Expanded, Journal Citation Reports, Index Copernicus, Lilacs, and Qualis B2 Capes databases, and licensed by Creative Commons®. Registered in the 1st Office of Registration of Deeds and Documents of São Paulo under n. 1.083, Book B, n. 2.

Publication norms are available on the website www.ramb.org.br

All rights reserved and protected by Law n. 9.610 – 2/19/1998. No part of this publication may be reproduced without prior written authorization of the AMB, whatever the means employed: electronic, mechanical, photocopying, recording or other.

THE RAMB IS INDEXED IN SCIELO - SCIENTIFIC ELECTRONIC LIBRARY ONLINE.



TIMBRO EDITORA

PUBLISHER: *Rodrigo Aguiar*

AUTHORIZING EDITOR: *Luciano Bauer Grohs*

EDITOR: *Celina Maria Morosino Lopes*

PRODUCER: *Maria Fortes*

EDITORIAL PRODUCER: *Helvânia Ferreira*

ENGLISH TRANSLATION OF ARTICLES: *Alpha & Omega*

REFERENCE REVIEWER: *Rosângela Monteiro*

PROOFREADING: *Hebe Ester Lucas e Alpha & Omega*

GRAPHIC DESIGN: *Angela Mendes e Murilo M. Camargo*



The advertisements and opinions published in the Ramb are the sole responsibility of the advertisers and authors. The AMB and Timbro Comunicação are not responsible for its content.

Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4⁺CD8⁺ double positive T lymphocytes as a new marker

 Yasin Kalpakci¹
 Tuba Hacibekiroglu²
 Gulay Trak³
 Cengiz Karacaer⁴
 Taner Demirci⁵
 Havva Kocayigit⁶
 Cenk Sunu⁷
 Ceyhun Varim⁸
 Mesude Falay⁹

1. Medical Doctor, Department of Hematology, Sakarya University Medicine Faculty, Sakarya, Turkey.
2. Associate Professor, Department of Hematology, Sakarya University Medicine Faculty, Sakarya, Turkey.
3. Medical Doctor, Department of Microbiology, Sakarya University Medicine Faculty, Sakarya, Turkey.
4. Medical Doctor, Department of Internal Medicine, Sakarya University Medicine Faculty, Sakarya, Turkey.
5. Assistant Professor, Department of Internal Medicine Division of Endocrinology, Sakarya University Medicine Faculty, Sakarya, Turkey.
6. Medical Doctor, Department of Anesthesiology, Sakarya University Medicine Faculty, Sakarya, Turkey.
7. Associate Professor, Department of Internal Medicine, Sakarya University Medicine Faculty, Sakarya, Turkey.
8. Medical Doctor, Department of Hematology, Duzen Laboratory Group, Istanbul, Turkey.
9. Hematology, Ankara Numune Training and Research Hospital, Ankara, Turkey

SUMMARY

BACKGROUND: The COVID-19 pandemic has affected the entire world, posing a serious threat to human health. T cells play a critical role in the cellular immune response against viral infections. We aimed to reveal the relationship between T cell subsets and disease severity.

METHODS: 40 COVID-19 patients were randomly recruited in this cross-sectional study. All cases were confirmed by quantitative RT-PCR. Patients were divided into two equivalent groups, one severe and one nonsevere. Clinical, laboratory and flow cytometric data were obtained from both clinical groups and compared.

RESULTS: Lymphocyte subsets, CD4⁺ and CD8⁺ T cells, memory CD4⁺ T cells, memory CD8⁺ T cells, naive CD4⁺ T cells, effector memory CD4⁺ T cells, central memory CD4⁺ T cells, and CD3⁺CD4⁺ CD25⁺ T cells were significantly lower in severe patients. The naive T cell/CD4⁺ + EM T cell ratio, which is an indicator of the differentiation from naive T cells to memory cells, was relatively reduced in severe disease. Peripheral CD4⁺CD8⁺ double-positive T cells were notably lower in severe presentations of the disease (median DP T cells 11.12 μ L vs 1.95 μ L; $p < 0.001$).

CONCLUSIONS: As disease severity increases in COVID-19 infection, the number of T cell subsets decreases significantly. Suppression of differentiation from naive T cells to effector memory T cells is the result of severe impairment in adaptive immune functions. Peripheral CD4⁺CD8⁺ double-positive T cells were significantly reduced in severe disease presentations and may be a useful marker to predict disease severity.

KEYWORDS: COVID-19, Lymphocyte Subsets, Adaptive Immunity.

RESUMO

OBJETIVO: A pandemia de COVID-19 tem afetado o mundo todo, constituindo uma ameaça grave para a saúde humana. As células T desempenham um papel crítico na imunidade celular contra infecções virais. Procuramos desvendar a relação entre sub grupos de células T e a severidade da doença.

MÉTODOS: Um total de 40 pacientes com COVID-19 foram aleatoriamente recrutados para o presente estudo transversal. Todos os casos foram confirmados por RT-PCR quantitativo. Os pacientes foram divididos em dois grupos equivalentes, um grave e um não-grave. Os dados da avaliação clínica, laboratorial e da citometria de fluxo foram obtidos para ambos os grupos e comparados.

RESULTADOS: Os subconjuntos de linfócitos, células T CD4⁺ e CD8⁺, células T de memória CD4⁺, células T de memória CD8⁺, células T CD4⁺ virgens, células T efetoras CD4⁺, células T de memória central CD4⁺ e células T CD3⁺ CD4⁺ CD25⁺ estavam significativamente mais baixas nos pacientes graves. A razão células T virgens/células T efetoras TCD4⁺, que é um indicador da diferenciação entre células T virgens e células de memória, estava relativamente reduzida em casos graves da doença. As células T duplo-positivas CD4⁺CD8⁺ periféricas estavam notavelmente mais baixas em casos graves da doença (mediana das células T DP: 11,12 μ L vs. 1,95 μ L; $p < 0,001$).

CONCLUSÃO: Conforme aumenta a gravidade da doença nos casos de COVID-19, o número de subconjuntos de células T diminui significativamente. A supressão da diferenciação de células T virgens para células T efetoras é o resultado do comprometimento grave das funções imunológicas adaptativas. As células T duplo-positivas CD4⁺CD8⁺ periféricas estavam notavelmente mais baixas em casos graves da doença e podem ser um marcador útil para prever a severidade da doença.

PALAVRAS-CHAVE: COVID-19, Subconjuntos de linfócitos, Imunidade adaptativa.

INTRODUCTION

Most patients with COVID-19 are asymptomatic or have only mild symptoms¹. Symptomatic cases mostly suffer from mild fever, cough, shortness of breath, muscle pain, headache, and diarrhea^{2,3}. COVID-19 can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), multiple organ failure, and, eventually, death in patients with advanced age and severe comorbid diseases^{2,4}. One of the most implicated mechanisms in severe disease is immune system alterations⁵⁻⁷.

The physiopathology of COVID-19 and the underlying mechanisms in severe cases are the most important challenges of the ongoing studies. Several studies have highlighted that coronaviruses such as SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus), MERS-CoV (Middle East Respiratory Syndrome-Coronavirus), SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) leads to a severe reduction in T lymphocyte subsets, which are not common in other viral infections^{8,9}. Studies have focused on revealing the immune system changes to explain pathogenesis. In severe cases of the disease, memory T cell and regulatory T cell changes may be responsible for the uncontrolled inflammatory response and the lack of specific immunity.

METHODS

Study Design and Participants

This study was designed as a cross-sectional study. The diagnosis was confirmed by quantitative RT-PCR. A total of 40 patients over 18 years old were recruited randomly in the study. The patients were divided into two equivalent groups, according to clinical and laboratory findings, i.e., severe and nonsevere. Written informed consent was obtained from all participants. Patients using convalescent plasma, tocilizumab, and systemic steroids were excluded.

Definitions

The Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by the National Health Commission & State Administration of Traditional Chinese Medicine on March 3, 2020) was used to define the severity of the disease¹⁰. Patients were classified as mild/moderate/severe/critical according to this protocol. We defined mild/moderate cases as nonsevere and severe/critical cases as severe. Cases with respiratory distress (≥ 30 breaths/min), oxygen saturation $\leq 93\%$ at rest, arterial partial pressure of oxygen (PaO₂) fraction of inspired oxygen (FiO₂) ≤ 300 mmHg (1 mmHg = 0.133kPa), and all cases requiring mechanical ventilation support or having any organ failure due to COVID-19 were included in the severe group; cases that did not meet these criteria were included in the nonsevere group.

Data Collection

Demographic data and laboratory findings including complete blood count, routine serum biochemical tests, acute phase and infection indicators, and coagulation parameters were collected from inpatient records. Lymphocyte subsets were analyzed from fresh blood samples by flow cytometry. We used the dual-platform flow cytometric method to measure (DP FCM) the lymphocyte subsets^{11,12}. All other clinical and laboratory data were collected simultaneously with a flow cytometric analysis.

Flow Cytometry

On the same day of the analysis, 4-5 ml of peripheral blood samples were taken from the tubes containing EDTA and sent to the microbiology laboratory of our hospital without waiting. Peripheral blood samples in tubes containing EDTA were labeled using monoclonal antibodies. For this purpose, the number of cells was calculated to be 1×10^6 cells per mL. Lymphocyte subsets were analyzed by flow cytometry as previously described in

the literature.¹³ Subsets were determined using antibodies as follows: CD3 (FITC) / CD4 (PeCY7) / CD8 (APC Cy7) / CD45ROPE / CD45RA (APC) / CD197 (PerCpCy5,5) / CD25 (APC Cy7) (BD Biosciences, AB). The tubes were incubated for 20 minutes at room temperature in the dark. At the end of the incubation, the red blood cells in the samples were removed by adding 2-3 mL of Lysing Solution (Becton Dickinson, San Jose, CA 95131 USA). Following washing with Lysing Solution, they were washed with 2 mL of PBS (Phosphate Buffer Saline), the cells were suspended with 500 μ L of PBS containing 1% paraformaldehyde and kept in the dark at 2-8 °C until the time of analysis. The cells were analyzed with the FACSCantoII (Becton Dickinson, Immunocytometry Systems, San Jose, CA 95131 USA) model flow cytometry device using the BD FACS-Diva program.

Statistical Analysis

Statistical analysis was performed with SPSS Statistics (IBM Corporation, Somers, NY) software, version 22). The normality of the distribution of continuous variables was determined using the Kolmogorov-Smirnov test. The continuous variables were expressed as mean and standard deviation or as median and interquartile range, depending on the normality of their distribution. Categorical variables are interpreted by frequency tables. The Mann-Whitney U test was used to compare the variables that were not normally distributed. On the other hand, the Student's t-test was used to compare the variables with a normal distribution. Categorical features and relationships between the groups were assessed using an appropriate chi-square test. A p-value of <0.05 was accepted as statistically significant.

RESULTS

Demographic and Basic Clinical Features of Severe and Nonsevere COVID-19 Patients

The demographic features, basic clinical and laboratory characteristics of the 40 patients are presented in Table 1. While there was no significant difference in the women and men ratio, patients in the severe disease group were significantly older (mean age of severe patients: 71.9 ± 11.2; non-severe patients: 55.4 ± 17.0, p<0.001). There were 3 patients with concomitant malignancy and 20 patients with a comorbid chronic metabolic disease, and the differences between the two groups were not significant, but the number of patients was insufficient for interpretation.

Biochemical and Inflammatory Markers, Blood Cell Counts Representing Disease Severity

The inflammatory and biochemical markers (C-reactive protein, erythrocyte sedimentation rate, procalcitonin, d-dimer, ferritin, fibrinogen, and lactate dehydrogenase) were found to be significantly elevated in the severe disease group (Table 1). In the severe disease group, the white blood cell count (WBC) and absolute neutrophil count (ANC) increased considerably, whereas a critical decrease in the absolute lymphocyte count (ALC) was noticed, with no distinct difference in platelet counts (WBC 8.86±3.51 vs 5.89±2.30 10³/mm³; p=0.003, ANC 7.72±3.41 vs 3.67±2.01 10³/mm³; p<0.001, ALC 0.61 vs 1.39 10³/mm³; p<0.001, platelet count 221.6±123.8 vs 199.5±100.3 10³/mm³; p=0.538 respectively). The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were increased significantly in the severe disease group (NLR 10.55 vs 2.21; p<0.001, PLR 319.5 vs 119.5; p<0.001).

Comparison of Lymphocyte Subsets and Memory T cells According to Disease Severity

Lymphocyte subsets were compared according to disease severity and are presented in Table 2. CD8+ cytotoxic T cells and CD4+ helper T cells were significantly lower in

patients with severe disease (CD8+ T cells 192.00 vs 504.15 µL; p<0.001, CD4+ T cells 395.45 vs 958.83 µL; p<0.001); however, there was no significant difference in the CD4/CD8 ratio in both groups (CD4/CD8 ratio 1.81 vs 1.57; p=0.738). Memory T cells showed a remarkable decrease in the severe disease group (CD4+ memory T cells 304.99 ± 204.75 vs 682.38 ± 269.26 µL; p<0.001, CD8+ memory T cells 87.61 vs 288.33 µL; p<0.001). The naive, EM, and CM CD4+ T cells were notably reduced in the severe disease group (Naive T cells 175.06 vs 502.68 µL; p<0.001, EM 0 vs 14.61 µL; p=0.015, CM 475.74 vs 1051.68 µL; p<0.001). Furthermore, the naive CD4+ T cell/CD4+ effector memory T cells ratio was significantly impaired in patients with severe disease (median 0 vs 35.10; p<0.001). The CD3+CD4+CD25+ T cell subset was significantly lower in the severe disease group (374.42 vs 965.96 µL; p<0.001). As a new finding, CD4+CD8+ double-positive (DP) T lymphocytes

in peripheral blood decreased significantly in the severe disease group (DP T cells 1.95 vs 11.12 µL; p<0.001, respectively). The comparison of lymphocyte subsets is presented schematically in Figure 1.

DISCUSSION

Many studies have shown that advanced age and concomitant diseases are risk factors for severe COVID-19. In severe COVID-19 cases, adaptive immunity cannot overcome the disease and the virus spreads through the blood and damages tissues. In addition to virus-induced direct cytopathic damage, the development of organ injuries secondary to the uncontrolled release of cytokines (called cytokine storm) is believed to be responsible for the pathogenesis of the disease in severe cases^{5,14,15}.


Previous publications have reported that the neutralizing Ig-G antibodies last over 1-2 years in SARS-CoV and MERS-CoV infections¹⁶⁻¹⁹. However, recent studies have reported

TABLE 1. DEMOGRAPHIC FEATURES OF PATIENTS AND COMPARISON OF INFLAMMATORY MARKERS AND BLOOD CELL COUNTS ACCORDING TO THE CLINICAL SEVERITY OF THE DISEASE.

	Nonsevere patients (n=20)	Severe patients (n=20)	P-value
Age, years	55.4 ± 17.0	71.9 ± 11.2	0.001
Gender, F/M (%)	13/7 (65/35)	7/13 (35/65)	0.056
Chronic diseases			
No (%)	12 (60)	5 (25)	0.081
*Other chronic diseases(%)	7 (35)	13 (65)	
Malignancy (%)	1 (5)	2 (10)	
C-reactive protein (CRP), mg/L	12.10 (3.31-38.80)	167.50 (85.55-190.0)	<0.001
Sedimentation, mm/1 hr	43.11 ± 29.08	79.15 ± 23.27	<0.001
Procalcitonin, ng/mL	0.062 (0.034-0.079)	0.726 (0.197-3.232)	<0.001
Albumin, gr/L	36.4 ± 3.5	23.8 ± 3.6	<0.001
D-dimer, ng/mL	663.5 (346.5-1205)	2120 (1612.5-4300)	<0.001
Ferritin, ng/mL	120.9 (44.3-427.4)	864.5 (460.4-2000.0)	<0.001
Fibrinogen, mg/dL	348.0 (294.5-381.0)	477.5 (390.8-609.8)	<0.001
Lactate dehydrogenase (LDH), IU/L	223.5 (211-262.5)	395 (308-502.5)	<0.001
White blood cell count, 10 ³ / mm ³	5.89±2.30	8.86±3.51	0.003
Absolute neutrophil count, 10 ³ / mm ³	3.67±2.01	7.72±3.41	<0.001
Absolute lymphocyte count, 10 ³ / mm ³	1.39 (1.16-2.25)	0.61 (0.38-0.97)	<0.001
Platelet count, 10 ³ / mm ³	199.5±100.3	221.6±123.8	0.538
Neutrophil lymphocyte ratio (NLR)	2.21 (1.38-2.94)	10.55 (6.56-22.63)	<0.001
Platelet lymphocyte ratio (PLR)	119.5 (94.1-155.4)	319.5 (184.0-604.7)	<0.001

*Due to the low number of patients, patients with diabetes mellitus, hypertension, coronary heart disease, chronic kidney disease, and chronic inflammatory diseases were not demonstrated in the chronic metabolic disease group.

FIGURE 1. LYMPHOCYTE SUBTYPES ACCORDING TO THE CLINICAL SEVERITY OF THE DISEASE DEMONSTRATED SCHEMATICALLY.



Note. The data defined on the Y axis shows the absolute cell count per 1 microliter.

that neutralizing antibodies begin to decrease after 2-3 months in convalescent COVID-19 patients and many of them become negative in a short time¹⁹⁻²¹. The short-term reduction and disappearance of neutralizing antibodies in convalescent COVID-19 patients may suggest that the virus causes deeper and permanent impairments to the immune system's memory functions.

In this study, we aimed to contribute to the explanation of the pathogenesis of the disease by comparing T lymphocyte subsets in severe and nonsevere COVID-19 patients and revealing disorders of the T-cell-mediated immune response. Thus, we

analyzed CD4+ T helper cells, CD8+ cytotoxic T cells, memory T cells (CD4 and CD8 positive), CD3+CD4+CD25+ T cells, CD4+CD8+ double-positive (DP) T cells, which are important components of T-cell-mediated immunity.

The severe cases of the disease were significantly older (Table 1). The production of naive T cells and memory T cells decreases with aging²². The weakened adaptive immune response in the elderly can explain the increased severity of the disease with age. We found that CRP, ESR, procalcitonin level, which show the severity of the infection and reflect the inflammatory response, were significantly high in patients with severe

disease (Table 1). LDH, fibrinogen, d-dimer, ferritin, which are biochemical indicators of inflammation, were higher in patients with severe disease, and albumin was significantly lower in severe disease cases (Table 1). Lymphopenia is the first indicator of impairment in T-cell-mediated immunity. The prognostic ratios such as NLR and PLR increased notably in patients with severe disease as a result of decreased ALC (Table 1).

CD4+ T helper cells activate other immune cells and help B cells in the production of antibodies, while CD8+ cytotoxic T cells kill virus-infected cells directly with their granules. Persistent stimulation of viral

TABLE 2. COMPARISON OF LYMPHOCYTES SUBSETS BY CLINICAL SEVERITY OF THE DISEASE.

	Nonsevere patients (n=20)	Severe patients (n=20)	P-value
CD4+ T cells, μ L	958.83 \pm 416.24	395.45 \pm 237.59	<0.001
CD8+ T cells, μ L	504.15 (313.61 – 786.22)	192.00 (135.52 – 261.80)	<0.001
CD4+ memory T cells, μ L	682.38 \pm 269.26	304.99 \pm 204.75	<0.001
CD8+ memory T cells, μ L	288.33 (178.94 – 492.92)	87.61 (52.15 – 148.52)	<0.001
CD4+ effector memory T cells, μ L	14.61 (4.34 – 21.47)	0 (0 – 12.15)	0.015
CD4+ central memory T cells, μ L	1051.68 \pm 427.16	475.74 \pm 298.57	<0.001
CD3+CD4+CD25+ T Cells, μ L	965.96 \pm 416.58	374.42 \pm 224.00	<0.001
Naive CD4+ T cell, μ L	502.68 (358.26 – 746.01)	175.06 (58.20 – 259.61)	<0.001
CD4+CD8+ double positive T cells μ L	11.12 (7.61 – 21.71)	1.95 (0 – 17.66)	<0.001
CD4/CD8 lymphocyte ratio	1.57 (1.38–2.85)	1.81 (1.16–3.13)	0.738
Naive CD4+ T cell/ CD4+ memory T cells ratio	0.92 \pm 0.40	0.80 \pm 0.82	0.583
Naive CD4+ T cell/ CD4+ central memory T cells ratio	0.59 \pm 0.31	0.59 \pm 0.96	0.998
Naive CD4+ T cell/ CD4+ effector memory T cells ratio	35.10 (15.83–102.20)	0 (0–14.14)	<0.001

infection and increased inflammatory cytokines lead to a depletion of T cells²³. In addition, the suggestion that SARS-CoV-2 infects T cells through spike-protein and increases apoptosis of T cells is still under investigation²⁴. Our study demonstrated that helper and cytotoxic T cells were significantly reduced in patients with severe disease. CD4/CD8 ratio has a crucial role in the management of some diseases, especially in HIV infection. However, we did not find a remarkable difference in the CD4/CD8 ratio between the two groups, therefore this is not a useful marker in COVID-19 management.

Normally, some of the naive T cells differentiate into long-lived memory cells after contact with a pathogen. Thus, they guarantee a much faster and stronger response when the same pathogen is encountered again. We have demonstrated that CD4+ memory T cells, CD8+ memory T cells, naive T cells, CD4+ EM T cells, and CD4+ CM T cells are critically reduced in severe disease cases (Table 2). We would like to point out that the naive T cell/CD4+ EM T cell ratio was impaired. As far as we know, a similar finding has been previously reported

only by Chuan Qin et al., who found that the naive-to-memory CD4+ T cell ratio was impaired in patients with severe disease⁵. These results suggest that the differentiation from naive T cells to EM T cells is also impaired.

We encountered a new finding to predict disease severity that has not been reported in previous studies. CD4+CD8+ double-positive (DP) T lymphocytes were remarkably lower in severe disease. DP T cells are present in peripheral blood in small numbers. Their roles in the pathogenesis of autoimmune diseases, viral infections, and cancers are under ongoing debate^{25–27}. Some studies have suggested that DP T cells are developing T cells released from the thymus, while others suggest that they are differentiated effector memory cells and have anti-viral effects^{27,28}. Michelina Nascimbeni et al. have offered that peripheral DP T cells are involved in the adaptive immune response to viral pathogens²⁷. The prominent reduction of peripheral DP T cells suggests that the adaptive immune response is seriously impaired in severe disease. DP T cells can be an important marker to predict severity if supported by larger studies.

Tregs regulates the immune response by suppressing the activation, proliferation, and cytokine production of CD4+ T cells and CD8+ T cells and are thought to suppress B cells and dendritic cells^{29,30}. Otherwise, excessive immune response and inflammation damage all tissues. As disease severity increases in COVID-19 infection, inflammation caused by uncontrolled cytokines becomes more and more severe, leading to organ failure. This well-known entity is called a cytokine storm. In our study, we compared the subset of CD3+ CD4+CD25+ T cells and found it to be significantly lower in patients with severe disease. Doubtless, CD25+ T cells do not fully represent Tregs, but they also contain them. Possibly the impairment in the regulatory functions is one of the leading pathologies that cause cytokine storms in patients with severe disease.

Our study has several limitations. First, this is a cross-sectional and single-center study with 40 patients. A prospective study with more participants and successive flow cytometric analysis would undoubtedly provide more valuable information. However, the high statistical significance in our results makes our study precious. Second, we could not compare all lymphocyte subsets due to the limited antibody supply and we couldn't identify Tregs exactly since CD127/FOXP3 was not available.

Despite the limitations, we obtained precious data regarding the adaptive immune response. In particular, we have demonstrated the importance of memory T cells and DP T cells in severe disease.

CONCLUSION

We have demonstrated that CD4+ helper T cells, CD8+ cytotoxic T cells, and memory T cells are significantly reduced in severe disease. The relative impairment in naive T cell/CD4+ effector memory T cell refers to deeper disorders in adaptive immune

functions of patients with severe disease. The decrease in DP T cells is a new and useful marker for predicting disease severity.

Conflicts of interest

All authors declare that there is no potential conflict of interest relevant to this article.

Author's Contribution

Writing - Review and Editing: Yasin Kalpakci; **Validation:** Tuba Hacibekiroglu; **Supervision:** Gulay Trak; **Resources:** Cengiz Karacaer; **Methods:** Taner Demirci; **Data curation:** Havva Kocayigit; **Conceptualization:** Cenk Sunu; **Visualization:** Ceyhun Varim; **Investigation:** Mesude Falay. ■

Submitted Date: 20-Jul-2020
Accepted Date: 20-Sep-2020

CORRESPONDING AUTHOR:

Yasin Kalpakci
Korucuk Mahallesi, Korucuk Caddesi,
ADA:3334, No 2118, Adapazari, Sakarya,
Turkey – 54260
Tel: +90 532 739-8495
Fax: +90 264 255-2105
E-mail: dryasin@live.com

REFERENCES

1. Gao, Z. et al. A Systematic Review of Asymptomatic Infections with COVID-19. *J. Microbiol. Immunol. Infect.* (2020) doi:10.1016/j.jmii.2020.05.001.
2. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395, 507–513 (2020).
3. Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* 323, 1061–1069 (2020).
4. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 497–506 (2020).
5. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108125/>.
6. Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Invest.* 130, 2620–2629 (2020).
7. Diao, B. et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). *Front. Immunol.* 11, 827 (2020).
8. XU, B. et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. *J. Infect.* 81, e51–e60 (2020).
9. Li, C. K. et al. T Cell Responses to Whole SARS Coronavirus in Humans. *J. Immunol.* 181, 5490–5500 (2008).
10. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia.
11. Who & Searo. Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS. (2007).
12. Böhrler, T. et al. Evaluation of a simplified dual-platform flow cytometric method for measurement of lymphocyte subsets and T-cell maturation phenotypes in the population of Nouna, Burkina Faso. *Clin. Vaccine Immunol.* 14, 775–781 (2007).
13. Machura, E., Mazur, B., Pieniżek, W. & Karczewska, K. Expression of naive/memory (CD45RA/CD45RO) markers by peripheral blood CD4 + and CD8 + T cells in children with asthma. *Arch. Immunol. Ther. Exp. (Warsz)*. 56, 55–62 (2008).
14. Coperchini, F., Chiovato, L., Croce, L., Magri, F. & Rotondi, M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine and Growth Factor Reviews* vol. 53 25–32 (2020).
15. Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19'. *Journal of Infection* vol. 80 607–613 (2020).
16. Wu, L. P. et al. Duration of antibody responses after severe acute respiratory syndrome. *Emerg. Infect. Dis.* 13, 1562–1564 (2007).
17. Choe, P. G. et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. *Emerg. Infect. Dis.* 23, 1079–1084 (2017).
18. Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery [18]. *New England Journal of Medicine* vol. 357 1162–1163 (2007).
19. Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat. Med.* 1–5 (2020) doi:10.1038/s41591-020-0965-6.
20. Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* 368, 860–868 (2020).
21. Wang, X. et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. *medRxiv* 2020.04.15.20065623 (2020) doi:10.1101/2020.04.15.20065623.
22. Weng, N. ping. Aging of the Immune System: How Much Can the Adaptive Immune System Adapt? *Immunity* vol. 24 495–499 (2006).
23. Ng, C. T., Snell, L. M., Brooks, D. G. & Oldstone, M. B. A. Networking at the level of host immunity: Immune cell interactions during persistent viral infections. *Cell Host and Microbe* vol. 13 652–664 (2013).
24. Wang, X. et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cellular and Molecular Immunology* 1 (2020) doi:10.1038/s41423-020-0424-9.
25. Overgaard, N. H., Jung, J.-W., Steptoe, R. J. & Wells, J. W. CD4 + /CD8 + double-positive T cells: more than just a developmental stage?. *J. Leukoc. Biol.* 97, 31–38 (2015).
26. Waschbisch, A. et al. Analysis of CD4+CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions. *Clin. Exp. Immunol.* 177, 404–411 (2014).
27. Nascimbeni, M., Shin, E. C., Chiriboga, L., Kleiner, D. E. & Rehermann, B. Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. *Blood* 104, 478–486 (2004).
28. Premature Escape of Double-Positive Thymocytes to the Periphery of Young Mice. Possible Role in Autoimmunity - PubMed. <https://pubmed.ncbi.nlm.nih.gov/8120365/>.
29. Romano, M., Fanelli, G., Albany, C. J., Giganti, G. & Lombardi, G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. *Frontiers in Immunology* vol. 10 43 (2019).
30. Shevryev, D. & Tereshchenko, V. Treg Heterogeneity, Function, and Homeostasis. *Frontiers in Immunology* vol. 10 3100 (2020).